Investigation of Sequence Clipping and Structural Heterogeneity of an HIV Broadly Neutralizing Antibody by a Comprehensive LC-MS Analysis
Open Access
- 7 May 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 29 (7), 1512-1523
- https://doi.org/10.1007/s13361-018-1968-0
Abstract
CAP256 is one of the highly potent, broadly neutralizing monoclonal antibodies (bNAb) designed for HIV-1 therapy. During the process development of one of the constructs, an unexpected product-related impurity was observed via microfluidics gel electrophoresis. A panel of complementary LC-MS analyses was applied for the comprehensive characterization of CAP256 which included the analysis of the intact and reduced protein, the middle-up approach, and a set of complementary peptide mapping techniques and verification of the disulfide bonds. The designed workflow allowed to identify a clip within a protruding acidic loop in the CDR-H3 region of the heavy chain, which can lead to the decrease of bNAb potency. This characterization explained the origin of the additional species reflected by the reducing gel profile. An intra-loop disulfide bond linking the two fragments was identified, which explained why the non-reducing capillary electrophoresis (CE) profile was not affected. The extensive characterization of CAP256 post-translational modifications was performed to investigate a possible cause of CE profile complexity and to illustrate other structural details related to this molecule’s biological function. Two sites of the engineered Tyr sulfation were verified in the antigen-binding loop, and pyroglutamate formation was used as a tool for monitoring the extent of antibody clipping. Overall, the comprehensive LC-MS study was crucial to (1) identify the impurity as sequence clipping, (2) pinpoint the clipping location and justify its susceptibility relative to the molecular structure, (3) lead to an upstream process optimization to mitigate product quality risk, and (4) ultimately re-engineer the sequence to be clip-resistant.Keywords
This publication has 21 references indexed in Scilit:
- An Artifact in LC-MS/MS Measurement of Glutamine and Glutamic Acid: In-Source Cyclization to Pyroglutamic AcidAnalytical Chemistry, 2014
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodiesNature, 2014
- HIV‐1 neutralizing antibodies: understanding nature's pathwaysImmunological Reviews, 2013
- Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing AntibodiesJournal of Virology, 2012
- Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell OntogeniesImmunity, 2012
- Optimal and consistent protein glycosylation in mammalian cell cultureGlycobiology, 2009
- Mass spectrometry for structural characterization of therapeutic antibodiesMass Spectrometry Reviews, 2008
- Determination of the origin of the N‐terminal pyro‐glutamate variation in monoclonal antibodies using model peptidesBiotechnology & Bioengineering, 2006
- Reversed-phase liquid chromatography/mass spectrometry analysis of reduced monoclonal antibodies in pharmaceuticsJournal of Chromatography A, 2006
- Carbamylation of Cysteine: A Potential Artifact in Peptide Mapping of Hemoglobins in the Presence of UreaAnalytical Biochemistry, 1999